文献速递瓣膜外科

风湿性心脏病二尖瓣修复与置换的倾向性评分对比研究

Outcomes of mitral valve repair compared with replacement for patients with rheumatic heart disease.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-02-14

该前瞻性观察研究纳入2011年1月至2019年4月接受二尖瓣修复或置换的风湿性心脏病患者,用倾向性评分匹配出1058例(529对)。中位随访4.12年,修复组全因死亡、早期死亡及瓣膜相关并发症风险均低于置换组,再手术风险两组无显著差异。

要点

  • 倾向性评分匹配后修复组全因死亡风险显著低于置换组(HR 0.38,95%CI 0.19-0.74,P=.003)。
  • 修复组瓣膜相关并发症风险低于置换组(SHR 0.44,95%CI 0.21-0.90,P=.025)。
  • 两组再手术风险无显著差异(SHR 2.54,95%CI 0.89-7.22,P=.081)。

核心结论

  • 在经选择的的风湿性心脏病患者中,二尖瓣修复较置换可降低死亡率和瓣膜相关并发症,再手术风险与置换相当。

研究设计与样本

  • 前瞻性观察性研究,2011年1月至2019年4月纳入风湿性心脏病行二尖瓣修复或置换患者,匹配前总体N=1644(修复612例,置换1032例),倾向性评分匹配后1058例(529对),中位随访4.12年。

主要发现

  • 修复组早期死亡风险显著低于置换组(HR 0.19,95%CI 0.05-0.64,P=.003)。
  • 修复组随访期间全因死亡风险显著低于置换组(HR 0.38,95%CI 0.19-0.74,P=.003)。
  • 修复组瓣膜相关并发症风险显著低于置换组(SHR 0.44,95%CI 0.21-0.90,P=.025)。
  • 修复组与置换组再手术风险无显著差异(SHR 2.54,95%CI 0.89-7.22,P=.081)。

临床怎么用

  • 对符合条件的风湿性心脏病患者,二尖瓣修复可作为优先考虑的手术策略,以降低死亡和瓣膜相关并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whether mitral valve repair is superior to replacement in the population with rheumatic heart disease has been debated. This study aims to compare outcomes of repair with replacement by the propensity score method. METHODS: This observational, prospective study enrolled patients with rheumatic heart disease who underwent mitral valve repair and replacement from January 2011 to April 2019. The propensity score method was used to select 2 groups with similar baseline characteristics. Baseline, clinical, and follow-up data were collected. Clinical outcomes included death from any cause, reoperation, and valve-related complications. RESULTS: The overall population before matching (N = 1644) included 612 patients who underwent repair and 1032 patients who underwent replacement. The propensity score analysis generated matches for 1058 patients (529 pairs). The median follow-up time was 4.12 years. Early mortality and death from any cause during follow-up were significantly lower in the repair group compared with the replacement group (hazard ratio, 0.19; 95% confidence interval [CI], 0.05-0.64; P = .003; hazard ratio, 0.38; 95% CI, 0.19-0.74; P = .003, respectively). Patients in the repair group had a lower risk of valve-related complications compared with patients in the replacement group (subhazard ratio, 0.44; 95% CI, 0.21-0.90; P = .025). In terms of reoperation, no significant difference was observed between the repair and replacement groups (subhazard ratio, 2.54; 95% CI, 0.89-7.22; P = .081). CONCLUSIONS: The results suggest that rheumatic mitral valve repair in select patients is superior to mitral valve replacement with regard to lower mortality and fewer valve-related complications; meanwhile, it has a comparable risk of reoperation compared with replacement.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Fu J, Li Y, Zhang H, et al. Outcomes of mitral valve repair compared with replacement for patients with rheumatic heart disease. J Thorac Cardiovasc Surg. 2020. PMID: 32169372. doi:10.1016/j.jtcvs.2020.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。